UCB's Global Corporate Website

This section is intended for media and financial analysts

Share Repurchase Program to cover UCB's Long Term Incentive Plans for its employees

Brussels (Belgium), 24 March 2020 – 20:00 (CET) – regulated information

In application of article 7:215 of the Belgian Code of Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) announces the launch of a share buy-back program (the “Share Repurchase Program 2020”), effective as of 25 March 2020. 

The repurchase of UCB shares under this program intends to cover current and future obligations under UCB's Long Term Incentive Plans for its employees. UCB will continuously monitor both its current and future obligations under such plans in view of keeping an adequate level of treasury shares.

Under this program, UCB may acquire from time to time its common stock, for a maximum of 1.2 million shares. The share repurchases will be conducted under the terms and conditions approved by the extraordinary general shareholders’ meeting of the Company held on 26 April 2018. The timing of the repurchase of shares pursuant to the program will depend on a variety of factors, including market conditions. The program may be suspended or discontinued at any time.

UCB has requested a financial intermediary to repurchase UCB shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 15 June 2020. 

During the Share Repurchase Program 2020, regular updates will be published in accordance with applicable legislation.

This press release is available on UCB SA/NV’s website via the following link.


Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 


About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Asset Download

Stay up-to-date on the latest news and information from UCB